Floatz logo

DYNAMOS

Epilepsy

GlaxoSmithKlineSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

77 Active assets in the Epilepsy cohort.

Asset / SponsorPhaseRating
Topamax
SK Life Science, Inc.
Phase 4BBB
Eslicarbazepine Acetate
Bial - Portela C S.A.
Phase 4BBB
Topamax
Université de Sherbrooke
Phase 4BBB
Carbamazepine
Assistance Publique - Hôpitaux de Paris
Phase 4BBB
Lacosamide
Second Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

DYNAMOS is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
60 / 100
View asset →
MASH - Metabolic Dysfunction-Associated SteatohepatitisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →